In China, an anti-human IL-8 monoclonal antibody cream has been approved for treating inflammatory skin diseases such as psoriasis and eczema.720 HuMax-IL8 (BMS-986253), another anti-IL-8 monoclonal antibody, exhibited a favorable safety and tolerability profile in solid tumor patients during a phase I clinical trial (NCT02536469).721. This evidence concerns the gene CXCL8 and Eczematoid dermatitis.